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into osteoblasts. Most bones are formed 
through the second mechanism, ‘endo-
chondral bone formation’, in which 
condensed mesenchymal cells initially 
differentiate into chondrocytes and 
produce cartilage matrix. The soft shell 
templates formed are subsequently 
replaced by osteoblasts and then ossi-
ﬁed (Figure 1). These sequential proc-
esses of endochondral bone formation 
are regulated in detail by many crucial 
genes and proteins.6
Involvement of endochondral bone 
formation in intimal calciﬁcation has 
already been indicated by the presence 
of chondrocytes and osteoblasts within 
calcified atherosclerotic plaques.7,8 
Until recently, direct differentiation 
into osteoblasts was suspected to be 
the major mechanism in the develop-
ment of medial calciﬁcation in CKD.9 
However, Neven and associates10 (this 
issue) now indicate the putative role 
of endochondral bone formation in 
medial calciﬁcation by demonstrating 
the presence of chondrocyte-like cells 
and the expression of speciﬁc markers 
for chondrocytes in the calciﬁed tunica 
media in an animal model of CKD and 
in humans.
These studies strongly support the 
involvement of endochondral bone for-
mation in both medial and intimal calci-
ﬁcation. Such ﬁndings certainly add new 
target points to be studied for establish-
ing eﬀective interventions for vascular 
calciﬁcation. So, what should be done to 
prove the functional involvement of this 
mechanism in vascular calciﬁcation?
The ﬁrst issue to be clariﬁed is whether 
all processes involved in endochondral 
bone formation take place in vascular 
Vascular calciﬁcation is a major abnor-
mality of mineral and bone metabolism 
in chronic kidney disease (CKD)1 and 
is one of the major determinants of 
the risk of cardiovascular events and 
survival in patients with CKD.2 In 
these patients, calcification develops 
not only in the intima, but also in the 
media of arteries, where it is known as 
Monckeberg’s medial sclerosis.3 As for 
the pathogenesis, it has recently been 
well accepted that vascular calciﬁcation 
is not a simple process of precipitation 
of supersaturated calcium phosphate4 
but also includes several mechanisms 
similar to those of bone formation in 
situ, such as expression of the osteob-
last diﬀerentiation factor core binding 
factor α-1 (Cbfa1) and bone-associated 
proteins.5 However, the similarities and 
diﬀerences between these processes have 
not yet been fully elucidated.
Bone tissue is formed mainly through 
two different mechanisms. The first 
is ‘membranous bone formation’, 
exclusively seen in cranial flat bone 
development. In this mechanism, mes-
enchymal cells directly differentiate 
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Vascular calcification, particularly of the medial layer of arteries, 
is one of the key determinants of survival in patients with chronic 
kidney disease. This abnormality is not merely a simple process of 
precipitation of calcium and phosphate but also includes several 
mechanisms similar to those of bone formation within the vessel wall.
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Figure 1 | Time course and processes of endochondral bone formation. Initially formed 
cartilage tissue is absorbed by hematopoietic stem cell-derived macrophage-like cells, and 
replaced by bone tissue. (a) Cartilage tissue (dark blue) is formed with a poor blood supply.  
(b) Blood vessels penetrate into the cartilage tissue through the perichondrium. (c) Hematopoietic 
stem cell-derived macrophage-like cells absorb cartilage tissue and form a primitive bone marrow. 
(d) A magnified image of peri-bone marrow tissue. (1) Proliferation of chondrocytes. (2) Active 
production of cartilage matrix by mature chondrocytes. (3) Focal calcification around the atrophic 
chondrocytes. (4) Destruction of calcified tissue by hematopoietic stem cell-derived chondroclasts/
osteoclasts. (5) Invasion of osteoblasts from bone marrow space through the tunnel created by 
chondroclasts/osteoclasts, and production of bone matrix.
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calciﬁcation. As can be seen from the 
anatomy of the auricle, the presence of 
chondrocytes does not necessarily mean 
the development of endochondral bone 
formation. Furthermore, calciﬁed and 
non-calciﬁed portions are clearly sepa-
rate in the bone. Thus, the time course 
needs to be demonstrated, and the initial 
mechanisms that trigger the transition 
from cartilage to bone tissue within the 
vessel wall need to be identiﬁed.
If medial calcification also involves 
the processes of endochondral bone for-
mation, another major issue remains to 
be clariﬁed. What are the essential dif-
ferences in the pathogenesis of calciﬁ-
cation in the intima and in the media? 
Because medial calciﬁcation is often seen 
in the elderly and in patients with CKD 
or diabetes, a number of factors have 
been examined, such as uremic tox-
ins, oxidative stress, and inﬂammation; 
however, they fail to explain the diﬀer-
ences clearly. Future breakthroughs are 
certainly required to establish eﬀective 
prevention and treatment modalities for 
medial calciﬁcation in CKD patients.
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Can we do better than a single 
estimated GFR threshold when 
screening for chronic kidney 
disease?
ED Poggio1 and AD Rule2
The Modification of Diet in Renal Disease (MDRD) equation has been 
used to screen for and diagnose chronic kidney disease (CKD). A fixed 
estimated glomerular filtration rate cutoff point has been advocated 
by the National Kidney Foundation to diagnose CKD. However, data 
derived from healthy individuals challenge this approach and suggest 
that age- and gender-specific reference values may be more useful in the 
screening setting.
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The publication of the Kidney Disease 
Outcomes Quality Initiative (KDOQI) 
guidelines by the National Kidney Founda-
tion (NKF) in 2002 provided the medical 
community for the ﬁrst time with a uni-
form deﬁnition of chronic kidney disease 
(CKD).1 These guidelines had the objec-
tive of timely management and treatment 
of this population at risk for increased 
mortality. This classiﬁcation of CKD is 
based on three fundamental components: 
(1) an anatomical or structural component 
as evidenced by the presence of parenchy-
mal renal disease (for example, abnormal 
imaging testing, abnormalities of the urine 
composition, and so on); (2) a temporal 
component in which the abnormalities 
are present for at least 3 months; and (3) a 
functional component based on glomeru-
lar ﬁltration rate (GFR). Although all three 
are critical, the level of GFR is the pivot for 
staging the disease and determining the 
applicability of the recommended KDOQI 
treatment and management guidelines. 
Because direct GFR measurements are 
expensive and inconvenient, estimated 
GFR (eGFR) by the abbreviated Modiﬁ-
cation of Diet in Renal Disease (MDRD) 
equation has been the tool chosen by the 
NKF.1 An important consideration is that 
these guidelines deﬁne and classify CKD 
irrespective of cause of renal disease and 
make no distinction based on gender and 
age.2 For example, patients with stage 
3 CKD (eGFR 30–59 ml/min/1.73 m2) 
are lumped together even though they 
represent a wide spectrum of ‘disease’ 
from a 35-year-old man with a progres-
sive glomerulonephritis to a 65-year-old 
woman without risk factors for CKD but 
with a high-normal serum creatinine 
level.
The MDRD equation was developed 
from nephrology referral patients identi-
ﬁed by an elevated serum creatinine level 
(≥1.2 mg/dl in women and ≥1.4 mg/dl in 
men).3 To emphasize an early diagnosis of 
CKD, the NKF and the National Kidney 
Disease Education Program (NKDEP) 
generalized the use of the equation and 
recommend that all laboratories automati-
cally report an eGFR with each serum cre-
atinine test measured, irrespective of the 
clinical setting in which the test has been 
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